Dublin, July 21, 2021 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.com's offering.
The Global Regenerative Medicine Partnering terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 1450 Regenerative Medicine deals.
The report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1450 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:
In-depth understanding of Regenerative Medicine deal trends since 2014
Access to headline, upfront, milestone and royalty data
Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
Identify most active Regenerative Medicine dealmakers since 2014
Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Regenerative Medicine dealmaking
2.2. Regenerative Medicine partnering over the years
2.3. Most active Regenerative Medicine dealmakers
2.4. Regenerative Medicine partnering by deal type
2.5. Regenerative Medicine partnering by therapy area
2.6. Deal terms for Regenerative Medicine partnering
2.6.1 Regenerative Medicine partnering headline values
2.6.2 Regenerative Medicine deal upfront payments
2.6.3 Regenerative Medicine deal milestone payments
2.6.4 Regenerative Medicine royalty rates
Chapter 3 - Leading Regenerative Medicine deals
3.2. Top Regenerative Medicine deals by value
Chapter 4 - Most active Regenerative Medicine dealmakers
4.2. Most active Regenerative Medicine dealmakers
4.3. Most active Regenerative Medicine partnering company profiles
Chapter 5 - Regenerative Medicine contracts dealmaking directory
5.2. Regenerative Medicine contracts dealmaking directory
Chapter 6 - Regenerative Medicine dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 - Regenerative Medicine deals by company A-Z
Appendix 2 - Regenerative Medicine deals by stage of development
Appendix 3 - Regenerative Medicine deals by deal type
Appendix 4 - Regenerative Medicine deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/v8fkhv
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900